Psoriatic Arthritis Treatment Market Forecast 2025-2034: Evaluating Growth Factors, Segments, and Emerging Trends

What Is the Forecasted Market Size and Growth Rate for the Psoriatic Arthritis Treatment Market?
Strong growth has been observed in recent years in the psoriatic arthritis treatment market, with predictions of an increase from $10.93 billion in 2024, to a market value of $12 billion in 2025. This represents a compound annual growth rate (CAGR) of 9.8%. Reasons for this acceleration in the historical period include an escalation in diagnosis rates, a rising prevalence of psoriatic arthritis, greater public awareness of psoriatic arthritis and its respective treatments, an enlarging selection of authorized psoriatic arthritis treatments, government backing for research and development, and heightened investment from pharmaceutical corporations.

The market for psoriatic arthritis treatment is anticipated to witness significant expansion in the forthcoming years. It is projected to rise to a value of $17.16 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.4%. Factors contributing to the growth during the forecasted period encompass personalized medication, the rise of biologics and small molecules, expanded treatment alternatives, and the global increase in aged populations. The expected trends within this period involve the progress in biologics, oral small molecules, the targeting of specific pathways, the evolution of telemedicine and remote monitoring, a focus on patient-centric care, and the application of real-world evidence.

What Factors Are Propelling the Expansion of the Psoriatic Arthritis Treatment Market?
The psoriatic arthritis treatment market has experienced an uptick in growth, primarily due to the amplified occurrence of psoriasis and psoriatic arthritis. Both psoriasis (PSO) and psoriatic arthritis (PsA) are inflammatory disorders that can greatly undermine an individual's overall health and quality of life. Psoriasis is intrinsically linked with an inflammatory arthritis known as psoriatic arthritis (PsA), which occurs in 30% of all psoriatic patients. In January 2024, research from the US-based National Library of Medicine revealed that each year, the percentage of psoriasis patients developing psoriatic arthritis fluctuates between 1.9% and 2.7% per 100 patients. Over the years, the risk of PsA development escalates notably, with rates marking 1.7% at 5 years, 3.1% at 10 years, and even scaling up to 20.5% at 30 years post psoriasis diagnosis. Consequently, the mounting prevalence of psoriasis and psoriatic arthritis fuels the growth of the associated market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp

Which Businesses Are at the Forefront of Psoriatic Arthritis Treatment Market Development?
Major companies operating in the psoriatic arthritis treatment market include AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., CB Biosciences Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Abbott Laboratories, Eisai Inc., Janssen Pharmaceuticals Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, LEO Pharma A/S, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.

What Are the Latest Innovations in the Psoriatic Arthritis Treatment Market?
Leading firms in the psoriatic arthritis treatment domain are concentrating their efforts on creating sophisticated products, such as targeted biologics, to provide superior and individualized treatment options. These new strategies aim to address the root causes of inflammation, improve patient prognosis, and significantly improve the lives of those afflicted by this long-term disease. Focusing on specific molecules involved in the proliferation and distribution of cancer cells, targeted biologic therapy uses specially engineered drugs or substances, with the goal of reducing harm to healthy cells and maximizing treatment effectiveness. An example of this is AbbVie, a biopharmaceutical company based in the United States, which announced in January 2022 that the U.S. Food and Drug Administration (FDA) has granted approval for SKYRIZI (risankizumab-rzaa). Specifically designed for the treatment of active psoriatic arthritis, SKYRIZI® (risankizumab-rzaa) is an interleukin-23 inhibitor that targets inflammation at its source by obstructing the p19 subunit of IL-23. Clinical trials have shown substantial improvements in joint symptoms and disease activity overall, with numerous patients achieving clinical remission and an improved quality of life. This therapy, administered through subcutaneous injection, presents a convenient choice for patients, allowing for adaptable dosing schedules suited to individual preferences.

How Is the Psoriatic Arthritis Treatment Market Segmented?
The psoriatic arthritis treatment market covered in this report is segmented -

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Topical
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors
2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs
3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics
4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

Where Is the Psoriatic Arthritis Treatment Market Growth Most Prominent?
The countries covered in the psoriatic arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

What Is Covered In The Psoriatic Arthritis Treatment Global Market Report?

- Market Size Analysis: Analyze the Psoriatic Arthritis Treatment Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Psoriatic Arthritis Treatment Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Psoriatic Arthritis Treatment Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Psoriatic Arthritis Treatment Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3458

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.